Permethrin


Northstar Rx Llc
Human Prescription Drug
NDC 16714-897
Permethrin is a human prescription drug labeled by 'Northstar Rx Llc'. National Drug Code (NDC) number for Permethrin is 16714-897. This drug is available in dosage form of Cream. The names of the active, medicinal ingredients in Permethrin drug includes Permethrin - 50 mg/g . The currest status of Permethrin drug is Active.

Drug Information:

Drug NDC: 16714-897
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Permethrin
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Prescription Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Permethrin
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Northstar Rx Llc
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Cream
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:PERMETHRIN - 50 mg/g
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:TOPICAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: ANDA
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 08 Apr, 2019
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 23 Dec, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: ANDA076369
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Northstar Rx LLC
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:106387
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
NUI:M0018228
N0000175847
Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT).
UNII:509F88P9SZ
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class EPC:Pyrethroid [EPC]
Established pharmacologic class associated with an approved indication of an active moiety (generic drug) that the FDA has determined to be scientifically valid and clinically meaningful. Takes the form of the pharmacologic class, followed by `[EPC]` (such as `Thiazide Diuretic [EPC]` or `Tumor Necrosis Factor Blocker [EPC]`.
Pharmacologic Class CS:Pyrethrins [CS]
Chemical structure classification of the drug product’s pharmacologic class. Takes the form of the classification, followed by `[Chemical/Ingredient]` (such as `Thiazides [Chemical/Ingredient]` or `Antibodies, Monoclonal [Chemical/Ingredient].
Pharmacologic Class:Pyrethrins [CS]
Pyrethroid [EPC]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
16714-897-011 TUBE in 1 CONTAINER (16714-897-01) / 60 g in 1 TUBE08 Apr, 2019N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Product Elements:

Permethrin permethrin permethrin permethrin butylated hydroxytoluene carbomer homopolymer type b (allyl pentaerythritol or allyl sucrose crosslinked) coconut oil glycerin glyceryl monostearate isopropyl myristate lanolin alcohols mineral oil ceteth-20 water sodium hydroxide formaldehyde off-white

Indications and Usage:

Indications and usage permethrin cream, 5% is indicated for the treatment of infestation with sarcoptes scabiei (scabies).

Warnings:

Warnings if hypersensitivity to permethrin cream, 5% occurs, discontinue use.

General Precautions:

General scabies infestation is often accompanied by pruritus, edema, and erythema. treatment with permethrin cream, 5% may temporarily exacerbate these conditions.

Dosage and Administration:

Dosage and administration adults and children thoroughly massage permethrin cream, 5% into the skin from the head to the soles of the feet. scabies rarely infests the scalp of adults, although the hairline, neck, temple, and forehead may be infested in infants and geriatric patients. usually 30 grams is sufficient for an average adult. the cream should be removed by washing (shower or bath) after 8 to 14 hours. infants should be treated on the scalp, temple, and forehead. one application is generally curative. patients may experience persistent pruritus after treatment. this is rarely a sign of treatment failure and is not an indication for retreatment. demonstrable living mites after 14 days indicate that retreatment is necessary.

Contraindications:

Contraindications permethrin cream, 5% is contraindicated in patients with known hypersensitivity to any of its components, to any synthetic pyrethroid or pyrethrin.

Adverse Reactions:

Adverse reactions in clinical trials, generally mild and transient burning and stinging followed application with permethrin cream, 5% in 10% of patients and was associated with the severity of infestation. pruritus was reported in 7% of patients at various times post-application. erythema, numbness, tingling, and rash were reported in 1 to 2% or less of patients (see precautions-general ). other adverse events reported since marketing permethrin cream, 5% include: headache, fever, dizziness, abdominal pain, diarrhea and nausea and/or vomiting. although extremely uncommon and not expected when used as directed (see doage and administration ), rare occurrences of seizure have been reported. none have been medically confirmed as associated with permethrin cream, 5% treatment.

Use in Pregnancy:

Pregnancy: teratogenic effects: pregnancy category b reproduction studies have been performed in mice, rats, and rabbits (200 to 400 mg/kg/day orally) and have revealed no evidence of impaired fertility or harm to the fetus due to permethrin. there are, however, no adequate and well-controlled studies in pregnant women. because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Pediatric Use:

Pediatric use permethrin cream, 5% is safe and effective in pediatric patients two months of age and older. safety and effectiveness in infants less than two months of age have not been established.

Geriatric Use:

Geriatric use clinical studies of permethrin cream, 5% did not identify sufficient numbers of subjects aged 65 and over to allow a definitive statement regarding whether elderly subjects respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. this drug is known to be substantially excreted by the kidney. however, since topical permethrin is metabolized in the liver and excreted in the urine as inactive metabolites, there does not appear to be an increased risk of toxic reactions in patients with impaired renal function when used as labeled.

Overdosage:

Overdosage no instance of accidental ingestion of permethrin cream, 5% has been reported. if ingested, gastric lavage and general supportive measures should be employed. excessive topical use (see dosage and administration ) may result in increased irritation and erythema.

Description:

Description permethrin cream, 5% is a topical scabicidal agent for the treatment of infestation with sarcoptes scabiei (scabies). it is available in an off-white, vanishing cream base. permethrin cream, 5% is for topical use only. chemical name – the permethrin used is an approximate 1:3 mixture of the cis and trans isomers of the pyrethroid 3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropanecarboxylic acid, (3-phenoxyphenyl) methyl ester. permethrin has a molecular formula of c 21 h 20 cl 2 o 3 and a molecular weight of 391.29. it is a yellow to light orange-brown, low melting solid or viscous liquid. active ingredient – each gram contains permethrin 50 mg (5%). inactive ingredients – butylated hydroxytoluene, carbomer homopolymer type b, fractionated coconut oil, glycerin, glyceryl monostearate, isopropyl myristate, lanolin alcohols, mineral oil, polyoxyethylene cetyl ethers, purified water, and sodium hydroxide. formaldehyde 1 mg (0.1%) is added as a preservative. 1t6n1-image 1.jpg

Clinical Pharmacology:

Clinical pharmacology permethrin, a pyrethroid, is active against a broad range of pests including lice, ticks, fleas, mites, and other arthropods. it acts on the nerve cell membrane to disrupt the sodium channel current by which the polarization of the membrane is regulated. delayed repolarization and paralysis of the pests are the consequences of this disturbance. permethrin is rapidly metabolized by ester hydrolysis to inactive metabolites which are excreted primarily in the urine. although the amount of permethrin absorbed after a single application of the 5% cream has not been determined precisely, data from studies with 14 c-labeled permethrin and absorption studies of the cream applied to patients with moderate to severe scabies indicate it is 2% or less of the amount applied.

Carcinogenesis and Mutagenesis and Impairment of Fertility:

Carcinogenesis, mutagenesis, impairment of fertility six carcinogenicity bioassays were evaluated with permethrin, three each in rats and mice. no tumorigenicity was seen in the rat studies. however, species-specific increases in pulmonary adenomas, a common benign tumor of mice of high spontaneous background incidence, were seen in the three mouse studies. in one of these studies there was an increased incidence of pulmonary alveolar-cell carcinomas and benign liver adenomas only in female mice when permethrin was given in their food at a concentration of 5000 ppm. mutagenicity assays, which give useful correlative data for interpreting results from carcinogenicity bioassays in rodents, were negative. permethrin showed no evidence of mutagenic potential in a battery of in vitro and in vivo genetic toxicity studies. permethrin did not have any adverse effect on reproductive function at a dose of 180mg/kg/day orally in a three-generation rat study.

How Supplied:

How supplied permethrin cream, 5% (w/w) is available as follows: 60 g tube (ndc 16714- 897 -01)

Information for Patients:

Information for patients patients with scabies should be advised that itching, mild burning and/or stinging may occur after application of permethrin cream, 5%. in clinical trials, approximately 75% of patients treated with permethrin cream, 5% who continued to manifest pruritus at 2 weeks had cessation by 4 weeks. if irritation persists, they should consult their physician. permethrin cream, 5% may be very mildly irritating to the eyes. patients should be advised to avoid contact with eyes during application and to flush with water immediately if permethrin cream, 5% gets in the eyes.

Package Label Principal Display Panel:

Package/label principal display panel rx only permethrin cream, 5%* for external use only. not for use in eyes. *w/w 60 g 1t6n1-permethrin-cream.jpg


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.